Reshaping the future of nanopharmaceuticals: ad iudicium.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21992178.
- Also identified by DOI 10.1021/nn2038252.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present views on the future development of biologics-based nanopharmaceuticals from a "high risk-high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.
Medical subject headings
- Drug Discovery
- Nanomedicine